Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $12,943,870.44 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 21,858 shares of Medpace stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $592.18, for a total value of $12,943,870.44. Following the transaction, the chief executive officer directly owned 833,627 shares in the company, valued at approximately $493,657,236.86. This trade represents a 2.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Medpace Trading Down 0.9%

MEDP stock opened at $606.60 on Thursday. The company has a market capitalization of $17.09 billion, a P/E ratio of 42.42, a PEG ratio of 2.67 and a beta of 1.42. The business has a 50 day simple moving average of $556.49 and a 200-day simple moving average of $440.30. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $626.26.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The business had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the company posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Barclays increased their target price on shares of Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a research note on Friday, October 24th. TD Cowen increased their price objective on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research report on Friday, October 24th. Jefferies Financial Group lifted their target price on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. Rothschild Redb cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Finally, Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus target price of $487.18.

Hedge Funds Weigh In On Medpace

Large investors have recently modified their holdings of the business. CIBC Bancorp USA Inc. purchased a new stake in shares of Medpace in the third quarter valued at approximately $283,000. Ariadne Wealth Management LP acquired a new stake in Medpace in the third quarter valued at $244,000. Wilmington Savings Fund Society FSB boosted its position in shares of Medpace by 124.1% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 130 shares of the company’s stock worth $67,000 after purchasing an additional 72 shares in the last quarter. Caerus Investment Advisors LLC purchased a new stake in shares of Medpace during the 3rd quarter worth $811,000. Finally, Sunbelt Securities Inc. grew its stake in shares of Medpace by 12.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 464 shares of the company’s stock worth $239,000 after purchasing an additional 51 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.